Development and validation of a preoperative 18F-PSMA-1007 PET/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study.

Baseline PET/CT Radiomics and Clinical Indicators for Pretreatment Response Prediction in Unresectable Hepatocellular Carcinoma: Model Development and Internal Validation.

IntroductionPretreatment prediction of benefit from targeted therapy plus immunotherapy remains uncertain in unresectable hepatocellular carcinoma (HCC). We developed and internally validated a model integrating baseline 18F-FDG PET/CT radiomics with clinical indicators.MethodsThis single-center retrospective study inc...

Predicting clinically significant prostate cancer in PI-RADS 3 lesions: an internally validated PSA density-based model with decision-curve analysis.

External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy.

PURPOSE [177Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)-comprising ECOG performance status >0, hemoglobin <10 g/dL...

Integrated model of MRI biomarkers and clinical factors for predicting pathologic response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Prediction of overall survival in patients with colorectal cancer using baseline 18F-FDG PET/CT radiomics

To predict 3-year overall survival (OS) in patients with colorectal cancer (CRC) using baseline 18 F-FDG PET/CT radiomics. This retrospective study entrolled 166 patients with colorectal cancer (CRC) , who were randomly assigned into a training cohort ( n  = 133) and an internal random hold-out validation cohor...

MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer

Objectives To characterize recurrence heterogeneity among patients with VI-RADS 2 non-muscle-invasive bladder cancer (NMIBC) and to develop and internally validate a recurrence-free survival (RFS) prediction model incorporating quantitative MRI features. Methods This retrospective study included 342 patients with patho...